ESMO-GC 2023 - ESMO Gynaecological Cancers 2023
Feb 23 - Feb 24, 2023 | BarcelonaSpain
LARVOL is not affiliated with ESMO Gynaecological Cancers 2023 and all trademarks, logos, and brand names are property of their respective owners
Showing 16 abstracts linked to Trials
ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss - results from the ENGOT/GYN1/NCRI ATARI trial
Discussion
Invited Discussant of abstract 34O5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the Phase III PAOLA-1/ENGOT-ov25 trial
Overall Survival of Niraparib with Individualized Starting Dose as Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer Adjusted for Subsequent PARPi Use in Placebo Group: Results from an Ad Hoc Interim Analysis for the Phase 3 NORA Study
Discussion
Invited Discussant of abstract 35ONiraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a post hoc analysis on efficacy by surgical timing and residual disease status in the phase III PRIME trial
Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): 5-year (y) progression-free survival (PFS) by molecular subgroup in the PAOLA-1/ENGOT-ov25 trial
PRIMA/ENGOT-OV26/GOG-3012 study: long-term conditional PFS
Validation study of the shallowHRDv2 assay for Homologous Recombination Deficiency (HRD) detection in high-grade ovarian carcinomas (HGOC) in the first-line setting, from the phase III PAOLA-1/ENGOT-ov25 trial
Phase 1 analysis of ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer
Expression of CD47 a potent ‘don’t eat me’ signal’ in ovarian cancer (OC): Correlation with other immune features and evolution under neoadjuvant chemotherapy (NACT), a GINEGEPS study
Molecular Alterations Predictive of Outcome in Early Staged Cervical Cancer : a translational investigation in the international validation study of sentinel node biopsy in early cervical cancer SENTICOL III
Evaluation of Antitumor Activity and Immunogenic Cell Death (ICD) Induction by MORAb-202 (Farletuzumab Ecteribulin) in Human Ovarian Cancer (OV) Models
NXP800 versus cisplatin in ARID1a-mutated Ovarian Clear Cell Carcinoma xenograft models
Demographics and survival outcomes in patients (pts) with advanced or recurrent (A/R) endometrial cancer (EC) in the English real-world (RW) setting
Real world data of Niraparib in platinum sensitive relapsed ovarian cancer: a multicenter experience of the MITO group
A phase II trial of Docetaxel/cisplatin chemotherapy followed by pelvic radiation therapy in patients with high-risk endometrial carcinoma after staging surgery